Active ingredient combination to counteract the bacterium staphylococcus hominis and for use in deodorant and / or antiperspirant preparation

Abstract

An active ingredient combination.

Description

[0001] Active ingredient combination against the bacterium Staphylococcus hominis and in deodorant and / or anti-itranspirant preparations

[0002] The present invention relates to combinations of active ingredients consisting of methylheptyl glycerin and butyloctanoic acid and / or laurie acid, as well as cosmetic or dermatological preparations containing the combination of active ingredients and their use as substances effective against the bacterium Staphylococcus epidermis.

[0003] Cosmetic products generally serve not only to make one look beautiful and attractive, but also contribute significantly to increased self-esteem and well-being. Accordingly, a wide variety of cosmetic products are used for daily cleansing and skin care.

[0004] One category of cosmetic products is deodorants and antiperspirants, which are applied under the arms to prevent unpleasant odors. These odors are caused by the decomposition of sweat, which is itself odorless, by bacteria. This decomposition process produces fatty acid residues, which characterize the typical, familiar smell of sweat. Although deodorants and antiperspirants are applied to the same area of ​​skin and have the same objective, they differ in their technical mechanisms of action.

[0005] Antiperspirants contain antiperspirant active ingredients that serve to inhibit and reduce perspiration. Antiperspirant active ingredients containing aluminum can clog the sweat glands.

[0006] Deodorants, on the other hand, are characterized by the fact that they do not impede the flow of perspiration. Instead, deodorants are understood to be products containing special antimicrobial agents that reduce the growth of bacteria. Consequently, the decomposition of odorless sweat is reduced, resulting in fewer unpleasant body odors.

[0007] One bacterium responsible for these foul-smelling body odors is Staphylococcus epidermis. Therefore, active ingredients and combinations of active ingredients are needed that limit the growth of this bacterium and, in particular, reduce its population as effectively as possible.

[0008] DE102005012476A1 describes how the population of Staphylococcus epidermis can be effectively inhibited. However, it provides no information on the currently available effective combination of active ingredients.

[0009] Last but not least, it is crucial to have as many different combinations of active ingredients as possible in order to give product developers as much freedom as possible in formulating their products.

[0010] Surprisingly, the requirements could be met by the objects of the invention.

[0011] A first object of the invention is an active ingredient combination comprising methylheptyl glycerin and butyloctanoic acid and / or laurie acid.

[0012] A preferred object of the invention is an active ingredient combination according to the invention comprising methylheptyl glycerin and butyloctanoic acid. A preferred object of the invention is an active ingredient combination according to the invention comprising methylheptyl glycerin and laurie acid.

[0013] Another object of the invention is a cosmetic preparation comprising the active ingredient combination according to the invention.

[0014] Another object of the present invention is the use of the active ingredient combination to reduce the number of bacteria of the bacterium Staphylococcus epidermis on human skin.

[0015] Another object of the present invention is the cosmetic use of the active ingredient combination for reducing the number of Staphylococcus epidermis bacteria on human skin. This use can advantageously be described as an odor-improving application.

[0016] It is pointed out that the reduction of bacteria on the skin cannot be considered a medical use under any circumstances, as it is an external reduction of bacteria. There is no intervention in the human organism. The application aims at... The Federal Food, Drug, and Cosmetic Act (FD&C Act) defines cosmetics according to their intended use as "articles intended to be rubbed, poured, sprinkled, or sprayed on the human body, inserted into the human body, or otherwise applied for the purpose of cleansing, beautifying, making more attractive, or altering appearance" [FD&C Act, para. 201(i)]. Products included in this definition are skin moisturizers, perfumes, lipsticks, nail polishes, eye and face makeup preparations, cleansing shampoos, perms, hair dyes, and deodorants, as well as any substances intended to be used as an ingredient in a cosmetic product.Cosmetic use must therefore be distinguished from medical use.

[0017] Last but not least, an object of the invention is a cosmetic deodorant and / or antiperspirant preparation comprising the active ingredient combination.

[0018] The invention also relates to the use of the active ingredient combination in a cosmetic deodorant and / or antiperspirant preparation.

[0019] The invention also relates to a non-therapeutic method for reducing the number of Staphylococcus epidermis bacteria on human skin by topical application of a deodorant and / or antiperspirant preparation comprising the active ingredient combination according to the invention.

[0020] Unless otherwise stated, all weight percentages (wt%) specified below are based on the total weight of the preparation according to the invention, which in this case is advantageously a deodorant preparation and / or an antiperspirant preparation.

[0021] If ratios of certain components are disclosed in the following description, these ratios refer, unless otherwise stated, to weight ratios of the components.

[0022] Unless otherwise stated, all tests and measurements were carried out under "normal conditions". The term "normal conditions" refers to 20°C, 1013 hPa, and a relative humidity of 50%. Where the expression "after application" or an equivalent temporal term is used in this disclosure, it always refers to a period of up to 48 hours after application.

[0023] The term "skin" refers exclusively to human skin.

[0024] According to the invention, it is advantageous if the weight ratio of the total weight of methylheptyl glycerin to the total weight of butyloctanoic acid and / or laurie acid is from 10:1 to 1:10, preferably from 5:1 to 1:5 and particularly preferably from 2:1 to 1:2.

[0025] If the active ingredient combination is used in a cosmetic preparation, it is advantageous according to the invention if the total content of the active ingredient combination is from 0.1 wt.% to 10 wt.%, preferably from 0.4 wt.% to 5 wt.% and particularly preferably from 0.6 wt.% to 2.5 wt.%, wherein the values ​​refer to the total weight of the preparation.

[0026] Advantageous preparations according to the invention are characterized in that methylheptyl glycerin is contained in a proportion of 0.05 wt.% to 3.0 wt.%, preferably 0.2 wt.% to 2.0 wt.% and particularly preferably 0.3 wt.% to 1.0 wt.%, wherein the values ​​refer to the total weight of the preparation.

[0027] Advantageous preparations according to the invention are characterized in that butyloctanoic acid and / or laurie acid are contained in a proportion of 0.05 wt.% to 5.0 wt.%, preferably 0.2 wt.% to 3.0 wt.% and particularly preferably 0.3 wt.% to 2.0 wt.%, wherein the values ​​refer to the total weight of the preparation.

[0028] The preparations of the present invention can be in various forms. Preferred preparation forms include, for example, a solution, a suspension, a water-in-oil (W / O) or oil-in-water (O / W) emulsion, or multiple emulsions, such as water-in-oil-in-water (W / O / W) or oil-in-water-in-oil (O / W / O) emulsions, a hydrodispersion or lipodispersion, or an aerosol. Furthermore, the preparations can also be in solid stick form, in which the stick material is transferred to the skin by abrasion. In an advantageous embodiment, the preparations according to the invention are emulsions containing further substances, such as fats, oils, waxes, and / or other fatty substances, as well as water and one or more emulsifiers, such as are commonly used for this type of formulation. Such emulsions can advantageously be formulated as a cream or lotion.

[0029] In a further advantageous embodiment, the preparations according to the invention are in the form of an alcoholic solution, preferably an ethanolic solution. In this embodiment, the preparations advantageously comprise an alcohol content, preferably an ethanol content of 20% to 99% by weight, in particular of 30% to 99% by weight, based on the total weight of the preparation. Due to their low viscosity, these preparations are particularly suitable for use in a pump atomizer that is operated without propellant gas.

[0030] Further embodiments include cosmetic products comprising a pressure vessel with a dispensing valve, a cosmetic preparation containing the active ingredient combination located in the pressure vessel, and a propellant, in particular propane, butane, and / or nitrogen, which are also contained in the pressure vessel. The amount of propellant is selected such that, upon opening the dispensing valve, the cosmetic preparation is dispensed along with the propellant. In this way, the preparation becomes sprayable and can be applied to the skin. For such products, alcoholic, anhydrous preparations or emulsions are advantageously used as the preparation. The mixing ratio of the alcoholic solution or emulsion with propellant is preferably in the range of 20 to 60 wt.%, in particular 30 wt.%, to 40 to 80 wt.%, in particular 70 wt.%, propellant.Advantageously, the ratio is in the range of 15% preparation to 85% propellant, or 30% to 70%, and particularly 60% preparation to 40% propellant, whereby these figures refer to the total weight of preparation and propellant. In other embodiments, these figures refer to the total volume of preparation and propellant.

[0031] Advantageous preparations of the invention are further characterized in that they additionally contain an antiperspirant active ingredient. It is particularly advantageous if the antiperspirant active ingredient is selected from the group of aluminum salts with the formula [Al₂(OH)₂]. m Cl n ], where m+n=6.

[0032] Examples of aluminium salts according to the invention are:

[0033] - Aluminum salts such as aluminum chloride AlCh, aluminum sulfate Ah(SO₄)₃ - Aluminum chlorides of the empirical molecular formula [Al₂(OH)₂] m Cl n ], where m+n=6

[0034] - Aluminum chlorohydrate [Al2(OH)sCI] x H2O (ACH)

[0035] Standard Al complexes: Locron P (Clariant), Locron L (Clariant), Micro-Dry (Reheis), ACH-331 (Summit), Aloxicoll PF 40 (Giulini).

[0036] - Activated Al complexes: Reach 501 (Reheis), AACH-324 (Summit), AACH-7171 (Summit), Aloxicoll P (Giulini), Aloxicoll SD100

[0037] - Aluminum sesquichlorohydrate [Ah OH sCh.s] x H2O

[0038] Standard Al complexes: Aluminum Sesquichlorohydrate (Reheis), AACH-308 (Summit)

[0039] - Activated Al complexes: Reach 301 (Reheis)

[0040] - Aluminum dichlorohydrate [Ah OH^Ch] x H2O

[0041] Furthermore, it is advantageous if at least one aluminum-zirconium salt is included as the antiperspirant active ingredient. Advantageously selected from the group are aluminum / zirconium trichlorohydrex glycine ([Al₄Zr(OH)₃Ch] x H₂O x Gly), aluminum / zirconium tetrachlorohydrex glycine ([Al₄Zr(OH)₂Cl₄] x H₂O x Gly), aluminum / zirconium pentachlorohydrex glycine ([Al₄Zr OH⁻sCl₃] x H₂O x Gly), aluminum / zirconium octachlorohydrex glycine ([Al₄Zr(OH)₂Cl₈] x H₂O x Gly), and the glycine-free aluminum / zirconium salts. Aluminum / zirconium tetrachlorohydrex glycine is particularly preferred.

[0042] It is particularly advantageous if the aluminum-containing antiperspirant active ingredient contains aluminum chlorohydrate, aluminum sesquichlorohydrate and / or aluminum / zirconium tetrachlorohydrex glycine, with aluminum chlorohydrate being the most preferred.

[0043] Advantageously, the total proportion of aluminum-containing antiperspirant active ingredients is from 1 wt.% to 30 wt.%, preferably from 2 wt.% to 25 wt.% and particularly preferably from 5 wt.% to 22 wt.%, based on the total weight of the preparation.

[0044] It is particularly advantageous if the proportion of aluminium chlorohydrate is from 1 wt.% to 30 wt.%, preferably from 2 wt.% to 25 wt.% and especially preferably from 5 wt.% to 22 wt.%, based on the total weight of the preparation.

[0045] Other advantageous embodiments of the invention are characterized in that they do not contain any aluminum-containing antiperspirant active ingredients as described and listed above. It is also advantageous if the preparations do not contain any other antibacterial active ingredients.

[0046] Furthermore, it is advantageous if the preparation also contains at least one or more perfume substances that are liquid under normal conditions. Advantageously selected perfume ingredients are chosen from essential oils, geraniol, geranyl acetate, linalool, linalyl acetate, tetrahydrolinalool, citronellol, citronellyl acetate, dihydromyrcenol, dihydromyrcenyl acetate, tetrahydromyrcenol, terpineol, terpinyl acetate, nopol, nopyl acetate, 2-phenyl benzyl alcohol, benzyl acetate, benzyl salicylate, benzyl benzoate, styrallyl acetate, amyl salicylate, dimethylbenzylcarbinol, trichloromethylphenylcarbinyl acetate, p-tert-butylcyclohexyl acetate, isononyl acetate, vetiveryl acetate, alpha-hexylcinamaldehyde, 2-methyl-3-(p-tert-butylphenyl)propanol, 2-methyl-3-(p-isopropylphenyl)propanal, 3-(p-tert--Butylphenyl) propanal, tricyclodecenyl acetate, tricyclodecenyl propionate, 4-(4-hydroxy-4-methylpentyl)-3-cyclohexenecarbaldehyde, 4-(4-methyl-3-pentenyl)-3-cyclohexenecarbaldehyde, 4-acetoxy-3-pentyltetrahydropyran, methyldihydrojasmonate, 2 -heptylcyclopentanone, 3-methyl -2-pentylcyclopentanone, n-decanal, 9-decenol-1, phenoxyethyl isobutyrate, phenylacetaldehyde dimethyl acetal, phenylacetaldehyde diethyl acetal, geranonitrile, citronellonitrile, cedryl acetate, 3-isocamphylcyclohephane, ethine, heliotropin, coumarin, eugenol, Vanillin, Diphenyloxide, Hydroxycitronellal, Ionone, Methylionone, Isomethylionone, Iron, cis-3-hexenol and esters thereof, indane musk fragrances, tetralin musk fragrances, isochromane musk fragrances, macrocyclic ketones, macrolactone muscrown, macrolactone muscrown brassylate, and aromatic nitro musk fragrances. Other perfume components that may be included but are not expressly preferred are listed in Arctander, Perfume and Flavor Chemicals (Chemicals) Vol.I and II (1969) and Arctander, Perfume and Flavour Materials of Natural Origin (1960).

[0047] Advantageously, the proportion of perfume substances that are liquid under normal conditions is 0.001 to 2 wt.%, preferably 0.005 to 1.5 wt.% and particularly preferably 0.01 to 1.4 wt.% based on the total weight of the preparation.

[0048] Andere Ausführungsformen enthalten ein oder mehr der Parfuminhaltstoff gewählt aus der Gruppe Alpha-Isomethyl Ionone, Anise Alcohol, Benzyl Alcohol, Benzyl Benzoate, Benzyl Cinnamate, Benzyl Salicylate, Butylphenyl Methylpropional, Cinnamal, Cinnamyl Alcohol, Citral, Citronellol, Coumarin, D-Limonene, Eugenol, Linalool, Amyl Cinnamal, Amylcinnamyl Alcohol, Evernia Furfuracea (Treemoss) Extract, Evernia Prunastri (Oakmoss) Extract, Farnesol, Geraniol, Hexyl Cinnamal, Hydroxycitronellal, Isoeugenol, Methyl 2-Octynoate, Acetyl Cedrene, Alpha-Pinene, Alpha-Santalol and Betasantalol, Alpha-Terpinene, Anethole, Benzaldehyde, Beta-Caryophyllene, Beta-Pinene, Camphor, Cedrus Atlantica Extract, Cinnamomum Zeylanicum Extract, Citrus Sinensis / Aurantium Dulcis Extract, Cymbopogon Citratus I Schoenanthus Extract, Damascenone, Damascene Delta, Damascone-Cis-Alpha, Damascone-Cis-Beta, Dimethyl Benzyl Carbinyl Acetate (Dmbca), Eucalyptus Extract, Eucalyptus Extract, Eugenia Caryophyllus Extract,Eugenyl Acetate, Laurus Nobilis Extract, Lavandula Hybrida Extract, Lavandula Officinalis Extract, Linalyl Acetate, Mentha Piperita Extract, Menthol, Methyl Salicylate, Narcissus Extract, Otne, Pelargonium Graveolens Extract, Peru Balsam Extracts and Distillates (Myroxylon Baisamum Var Pereirae), Pinus Mugo Extract, Pinus Pumila Extract, Propylidene Phthalide, Terpinolene, Trimethyl- Benzenepropanol, Turpentine, Verbena Absolute (Lippia Citriodora Kunth.), 3-Methyl-5- (2,2,3-Trimethyl-3-Cyclopentenyl)Pent-4-en-2-ol, Alpha-Terpineol, Amyl Salicylate, Carvone, Cinnamomum Cassia Extract, Citrus Aurantium Amara Extract, Citrus Bergamia Extract, Citrus Limonum Extract, Geranyl Acetate, Hexadecanolactone, Hexamethylindanopyran, Isoeugenyl Acetate, Jasmine Absolute (Grandiflorum), Juniperus Virginiana Extract, Pogostemon Cablin Extract, Rose Extract, Salicylaldehyde, Santalum Album Extract, Sclareol, Terpineol, Vanillin und Ylang Ylang Extracts.,

[0049] Andere vorteilhaft Ausführungsformen sind frei von Parfuminhaltstoffen gewählt aus der Gruppe Alpha-Isomethyl Ionone, Anise Alcohol, Benzyl Alcohol, Benzyl Benzoate, Benzyl Cinnamate, Benzyl Salicylate, Butylphenyl Methylpropional, Cinnamal, Cinnamyl Alcohol, Citral, Citronellol, Coumarin, D-Limonene, Eugenol, Linalool, Amyl Cinnamal, Amylcinnamyl Alcohol, Evernia Furfuracea (Treemoss) Extract, Evernia Prunastri (Oakmoss) Extract, Farnesol, Geraniol, Hexyl Cinnamal, Hydroxycitronellal, Isoeugenol, Methyl 2-Octynoate, Acetyl Cedrene, Alpha-Pinene, Alpha-Santalol and Betasantalol, Alpha-Terpinene, Anethole, Benzaldehyde, Beta-Caryophyllene, Beta-Pinene, Camphor, Cedrus Atlantica Extract, Cinnamomum Zeylanicum Extract, Citrus Sinensis / Aurantium Dulcis Extract, Cymbopogon Citratus I Schoenanthus Extract, Damascenone, Damascene Delta, Damascone-Cis-Alpha, Damascone-Cis-Beta, Dimethyl Benzyl Carbinyl Acetate (Dmbca), Eucalyptus Extract, Eucalyptus Extract, Eugenia Caryophyllus Extract,Eugenyl Acetate, Laurus Nobilis Extract, Lavandula Hybrida Extract, Lavandula Officinalis Extract, Linalyl Acetate, Mentha Piperita Extract, Menthol, Methyl Salicylate, Narcissus Extract, Otne, Pelargonium Graveolens Extract, Peru Balsam Extracts and Distillates (Myroxylon Balsamum Var Pereirae), Pinus Mugo Extract, Pinus Pumila Extract, Propylidene Phthalide, Terpinolene, Trimethyl- Benzenepropanol, Turpentine, Verbena Absolute (Lippia Citriodora Kunth.), 3-Methyl-5- (2,2,3-Trimethyl-3-Cyclopentenyl)Pent-4-en-2-ol, Alpha-Terpineol, Amyl Salicylate, Carvone, Cinnamomum Cassia Extract, Citrus Aurantium Amara Extract, Citrus Bergamia Extract, Citrus Limonum Extract, Geranyl Acetate, Hexadecanolactone, Hexamethylindanopyran, Isoeugenyl Acetate, Jasmine Absolute (Grandiflorum), Juniperus Virginiana Extract, Pogostemon Cablin Extract, Rose Extract, Salicylaldehyde, Santalum Album Extract, Sclareol, Terpineol, Vanillin und Ylang Ylang Extracts.,

[0050] The preparations can be applied to the skin once or several times as part of non-therapeutic, cosmetic treatment. In one embodiment, the preparations according to the invention are formulated for daily application to the skin.

[0051] Examples:

[0052] The following examples are intended to illustrate this invention, without limiting the invention to these examples. The numerical values ​​in the examples are percentages by weight, based on the total weight of the preparations.

[0053] Suspension tests were performed to demonstrate antimicrobial efficacy.

[0054] The bacterium S. epidermidis (ATCC 12228) was streaked from a cryotube prepared according to EN 12353 onto a suitable agar plate (TSA agar) and incubated at 37°C for 24 hours. A second passage was prepared from the grown bacteria and used in the suspension test.

[0055] One loop of bacteria was added to 10 mL of BHI medium and 5 g of 4 mm diameter glass beads and vortexed for 3 minutes. This bacterial suspension was then adjusted to an OD (optical density) of 0.1 and subsequently diluted to obtain a cell count of T10. 5 This bacterial suspension was obtained. It was then used for the test.

[0056] For the suspension test, 100 pL of the total drug solution to be tested, or in the case of controls, 100 pL of the reference medium (dilution medium), were placed in Eppendorf tubes. Subsequently, 100 pL of the bacterial suspension were added and vortexed. At time point t, a sample was taken from the controls.

[0057] The Eppendorf tubes were incubated in a thermoshaker at 37°C and 600 rpm (every 30 minutes for 1000 s). The optical density (OD 600 nm) was measured every 30 minutes. The growth rates of the samples were analyzed for evaluation. To determine efficacy, each sample was diluted 1:100 with neuralizing medium and vortexed. These dilutions were plated onto agar plates using a spiral plater. For the controls, both dilutions were plated, including the time point T=0 minutes. Finally, the plates were incubated at 37°C for 24 hours and subsequently evaluated using a countermat.

[0058] The reduction factor was determined during the evaluation. The reduction factor is the factor by which the cell count (CFU) of the test substance is reduced compared to the control.

[0059] Media:

[0060] The total active ingredient solution was prepared by dissolving 5 pl of a first active ingredient solution A and 5 pl of a second active ingredient solution B in 90 pl of dilution medium.

[0061] The active ingredient solution A comprises a first active ingredient A, which is listed in the table below. The total weight of active ingredient A is chosen such that the percentage value listed below refers to the total weight of the active ingredient in the total active ingredient solution.

[0062] The active ingredient solution B comprises a second active ingredient B, which is listed in the table below. The total weight of active ingredient B is chosen so that the percentage value listed below refers to the total weight of the active ingredient in the total active ingredient solution. If only active ingredient A is present, active ingredient solution B is a solution of 50% ethanol and 50% water.

[0063] The dilution medium (diluent) was selected as described in the German standard DIN EN 13727 December 2015 (DIN EN 13727:2015-12).

[0064] The neuraling medium was chosen as described in the German standard DIN EN 13727 December 2015 (DIN EN 13727:2015-12).

[0065] Samples and results:

[0066] The combinations tested were listed in the table above. The combination according to the invention shows particularly effective efficacy. A synergistic effect is present.

[0067] Further example recipes:

[0068] Roll-ons

[0069]

[0070] Aerosols

[0071] The filling ratio (bulk:propellant) can be selected from, among others, 10:90, 15:85, 30:70, or 50:50. These filling ratios refer to both volume and mass. Nitrogen, compressed air, and a propane-butane mixture (2:7) were used as propellant.

[0072]

[0073] Pump spray / atomizer

[0074] pens

Claims

Claims 1. Active ingredient combination comprising a) Methylheptyl glycerin and b) Butyloctanoic Acid and / or Lauric Acid.

2. Active ingredient combination according to claim 1 characterized in that the weight ratio of total weight of methylheptyl glycerin to total weight of butyloctanoic acid and / or laurie acid is from 10:1 to 1:10, preferably from 5:1 to 1:5 and particularly preferably from 2:1 to 1:

2.

3. Cosmetic preparation comprising the combination of active ingredients according to claim 1 or 2.

4. Preparation according to claim 3 characterized in that the total content of the active ingredient combination is from 0.1 wt.% to 10 wt.%, preferably from 0.4 wt.% to 5 wt.% and particularly preferably from 0.6 wt.% to 2.5 wt.%, wherein the values ​​refer to the total weight of the preparation.

5. Preparation according to one of claims 3 to 4 characterized in that methylheptyl glycerin is contained in a proportion of 0.05 wt.% to 3.0 wt.%, preferably 0.2 wt.% to 2.0 wt.% and particularly preferably 0.3 wt.% to 1.0 wt.%, wherein the values ​​refer to the total weight of the preparation.

6. Preparation according to one of claims 3 to 5 characterized in that Butyloctanoic Acid and / or Laurie Acid are contained in a proportion of 0.05 wt.% to 5.0 wt.%, preferably 0.2 wt.% to 3.0 wt.% and particularly preferably 0.3 wt.% to 2.0 wt.%, wherein the values ​​refer to the total weight of the preparation.

7. Preparation according to one of claims 3 to 6 characterized in that it additionally contains an antiperspirant active ingredient.

8. Preparation according to claim 7 characterized in that the antiperspirant active ingredient is selected from the group of aluminium salts with the formula [Al2(OH) m Cl n ], where m+n=6.

9. Preparation according to one of claims 3 to 8 characterized in that it contains one or more perfume substances that are liquid under normal conditions.

10. Preparation according to claim 9 characterized in that the proportion of the perfume substances that are liquid under normal conditions is 0.001 to 2 wt.%, preferably 0.005 to 1.5 wt.% and particularly preferably 0.01 to 1.4 wt.% based on the total weight of the preparation.

11. Use of the active ingredient combination according to claim 1 or 2 for reducing the number of bacteria of the bacterium Staphylococcus epidermis on human skin.

12. Use of the active ingredient combination according to claim 1 or 2 in a cosmetic deodorant and / or antiperspirant preparation.

Images